Jing-Wen Li Shu-Hui Cao Jian-Lin Xu Hua Zhong
10.1080/15384047.2019.1617568
Cancer Biol Ther
2019;20(9):1183-1186.
de novo met amplification egfr mutation egfr-tki nsclc intrinsic resistance
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/31131689/
Carcinoma, Non-Small-Cell Lung / genetics Drug Resistance, Neoplasm / genetics Gene Amplification Lung Neoplasms / genetics Protein Kinase Inhibitors / pharmacology Proto-Oncogene Proteins c-met / genetics
Carcinoma, Non-Small-Cell Lung / genetics Drug Resistance, Neoplasm / genetics Gene Amplification Lung Neoplasms / genetics Protein Kinase Inhibitors / pharmacology Proto-Oncogene Proteins c-met / genetics Case Reports Aged Antineoplastic Combined Chemotherapy Protocols / adverse effects Antineoplastic Combined Chemotherapy Protocols / therapeutic use Biomarkers, Tumor Biopsy Carcinoma, Non-Small-Cell Lung / diagnosis Carcinoma, Non-Small-Cell Lung / drug therapy ErbB Receptors / antagonists & inhibitors Humans Lung Neoplasms / diagnosis Lung Neoplasms / drug therapy Mutation Positron Emission Tomography Computed Tomography Protein Kinase Inhibitors / therapeutic use Biomarkers, Tumor Protein Kinase Inhibitors EGFR protein, human ErbB Receptors Proto-Oncogene Proteins c-met
PMC6741769
31131689
De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors
2019